Trial Profile

Comparing Medication Maintenance in Comprehensive Community and Pharmacy Settings to Enhance Engagement

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 26 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buprenorphine/naloxone (Primary) ; Naltrexone (Primary)
Indications Opioid-related disorders
Focus Therapeutic Use
Acronyms MATPharm

Most Recent Events

21 Aug 2022 Planned End Date changed from 31 Jul 2022 to 1 Oct 2022.
21 Aug 2022 Planned primary completion date changed from 25 Mar 2022 to 30 Sep 2022.
21 Aug 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com